Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Staphylococcal proliferation on skin models to investigate novel anti-infective treatments against dysbiosis.

Bioengineering & translational medicine·2026
Same author

HERA: a web server for host element reference-based aligner.

Nucleic acids research·2026
Same author

RegRegSEA: a web server for regulatory region set enrichment analysis of epigenomic data.

Nucleic acids research·2026
Same author

Probiotic Lactobacillus rhamnosus mitigates PBC-like features in Mcpip1-deficient mice via modulation of gut-liver crosstalk.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Benchmarking large language models for pathogen-disease classification in post-acute infection syndromes.

Briefings in bioinformatics·2026
Same author

mRNA Sequencing of Limbal Epithelial Cells and mRNA/miRNA Profiling of Limbal Stromal Cells in <i>PAX6</i>-Related Congenital Aniridia.

Cells·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer&#39;s Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.5K

Validating Alzheimer's disease micro RNAs using next-generation sequencing.

Andreas Keller1, Christina Backes1, Jan Haas2

  • 1Clinical Bioinformatics, Saarland University, Saarbrücken, Germany.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|January 26, 2016
PubMed
Summary
This summary is machine-generated.

This study validates a 12-microRNA (miRNA) blood signature for Alzheimer's disease (AD) detection. The findings show miRNAs can significantly aid in diagnosing AD and improving patient care.

Keywords:
Alzheimer's diseaseBiomarkerValidationmiRNA

More Related Videos

A Complete Pipeline for Isolating and Sequencing MicroRNAs, and Analyzing Them Using Open Source Tools
09:29

A Complete Pipeline for Isolating and Sequencing MicroRNAs, and Analyzing Them Using Open Source Tools

Published on: August 21, 2019

8.0K
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
09:26

Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR

Published on: January 22, 2014

16.0K

Related Experiment Videos

Last Updated: Mar 26, 2026

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer&#39;s Disease
04:22

Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease

Published on: May 20, 2024

1.5K
A Complete Pipeline for Isolating and Sequencing MicroRNAs, and Analyzing Them Using Open Source Tools
09:29

A Complete Pipeline for Isolating and Sequencing MicroRNAs, and Analyzing Them Using Open Source Tools

Published on: August 21, 2019

8.0K
Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR
09:26

Cerebrospinal Fluid MicroRNA Profiling Using Quantitative Real Time PCR

Published on: January 22, 2014

16.0K

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Alzheimer's disease (AD) diagnosis and care can be improved with molecular biomarkers.
  • Novel biomarker candidates require rigorous verification for clinical utility.

Purpose of the Study:

  • To validate a previously identified 12-microRNA (miRNA) blood-based signature for Alzheimer's disease (AD).
  • To assess the diagnostic potential of miRNAs in distinguishing AD from other neurological conditions.

Main Methods:

  • Next-generation sequencing (NGS) was used to analyze miRNA profiles.
  • Validation involved 103 AD cases, 77 unaffected controls, and 110 diseased controls (including mild cognitive impairment and multiple sclerosis).
  • Samples were sourced from the United States and Germany.

Main Results:

  • A significant overlap of 68 dysregulated miRNAs was found between the initial and validation cohorts (P = .0003).
  • The area under the receiver operator characteristic curve values for the miRNAs showed strong correlation (0.93, P <10(-16)).
  • Five hundred eighty miRNAs were detected in total blood samples.

Conclusions:

  • The validated miRNA signature shows strong potential for supporting AD diagnosis.
  • Blood-based miRNAs may serve as valuable, non-invasive biomarkers for AD patient care.